Atossa gains on Rare Pediatric Disease status for Duchenne asset
Source: SeekingAlpha
2025-12-11 10:37:03 ET
More on Atossa Therapeutics
- Seeking Alpha’s Quant Rating on Atossa Therapeutics
- Historical earnings data for Atossa Therapeutics
- Financial information for Atossa Therapeutics
Read the full article on Seeking Alpha
For further details see:
Atossa gains on Rare Pediatric Disease status for Duchenne asset
Atossa Therapeutics Inc.
NASDAQ: ATOS
ATOS Trading
1.96% G/L:
$5.21 Last:
15,237 Volume:
$5.23 Open:
ATOS Latest News
May 08, 2026 08:45:00 am
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 06, 2026 08:30:00 am
Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women
ATOS Stock Data
$42,239,054
7,796,787
11.03%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
